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the virus remains a combination of pegylated interferon (PegIFN)
alpha and ribavirin. In this speciﬁc genotype 4 population, there
is a major medical need for studies on natural history, new treat-
ments, and predictors of response.
We performed a study in a well-characterized cohort of HCV-4
patients, to investigate the association of IL28B polymorphism
with response to treatment or liver disease severity [2]. In our
article, our well-characterized unique large cohort was deﬁned
based on its ethnic origin. In this cohort, three different ethnic
groups were represented with 70 (43%) Egyptians, 53 (32%) Euro-
peans, and 37 (23%) Sub-Saharan Africans. A liver biopsy was per-
formed in 160 patients, of whom 78 (49%) had a mild ﬁbrosis
(F0–F1) and 82 (51%) a moderate to severe ﬁbrosis (F2–F4).
We did not observed an association between ﬁbrosis stage
and response to treatment; however, the proportion of patients
with cirrhosis (F4) was relatively small (17.1%). Eighty-two
patients received 48 weeks of PegIFNa and ribavirin. Among
these, 43 patients (52%) obtained an SVR and 39 failed treatment
(28 (32%) obtained a non-response and 11 (16%) were relapsers).
Among our treated patients, the proportion of rs12979860 CC
was 26.8%; CT was 52.4%, and TT was 20.8%. Since in genotype
4 patients the treatment will remain PegIFN and ribavirin for sev-
eral years, IL28B polymorphism may remain an important associ-
ated factor with response. Another study performed in Italy gave
similar results with an association between IL28B polymorphism
and SVR [3]. Of 112 treated patients (98 males, 75 of Egyptian
descent, 26 with cirrhosis) 103 were included in the ﬁnal analy-
sis; ﬁve discontinued treatment for non-virologic reasons and
four did not consent to genetic testing. Twenty-four (23%) were
genotype CC, 65 (63%) CT, and 14 (14%) TT. Overall, 50 (49%)
achieved an SVR: 21 (88%) CC patients versus 29 (37%) CT/TT.The impact of organ dysfunction in
Journal of Hepatology 2012 vFurther studies will be needed to demonstrate whether geno-
e 4-infected patients with good predictors of response, includ-
IL28B CC, may beneﬁt from shorten therapy.
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We were delighted to read the recent study from Shawcross et al.
which has reported the ﬁndings of a large and robust prospective
dataset examining the outcomes of patients with cirrhosis and
acute organ dysfunction admitted to the Liver ICU at King’s
College Hospital, London over a 7-year period (2000–2007) [1].
The study population of 563 ﬁrst admissions represents the larg-
est cohort described in the literature to date. The reported ICU
(51%) and hospital (59%) mortality rates are comparable to those
quoted in the majority of published datasets in recent years.
Whilst unarguably higher than the ICU and hospital mortality
rates of unselected general ICU admissions nationally (20% and
30%) [2], they are still notably lower than those reported by some
of the earlier publications in this ﬁeld [3].
This complex and challenging patient cohort all too frequently
ﬁnd themselves the focus of negative clinical bias and prognostic
pessimism due to entrenched anecdotal experiences and health-
care provider perceptions regarding ‘self inﬂicted’ illness. It is
therefore important that studies such as these examine current
trends in outcome, after all, the incidence of chronic liver disease
related hospital admissions and overall mortality is rising in the
UK [4] and is a growing area of signiﬁcant public health concern.Despite the quantitative success of this dataset, by virtue of its
specialist setting it represents a tertiary transplant centre experi-
ence. More relevant to non-transplant critical care centres, we
would like to draw your readers’ attention to the results of a
study performed in 2010, which reported on the outcomes of
patients with cirrhosis and critical illness from the general inten-
sive care units of two large non-transplant centres in London [5].
It suggested the hypothesis that the patient population seen out-
side of transplant centres present with a different clinical pheno-
type, and hence would demonstrate even better outcomes from
their critical illness episode. The study population of Shawcross
et al. was composed largely of in-patients already on the tertiary
liver wards (50%) or cases referred acutely from external second-
ary care centres (44%) who were deemed to require specialist
input. Only 6% (35/563) were admitted de novo via the emer-
gency department or ‘general’ wards from elsewhere within
King’s College Hospital. Table 1 shows the descriptive cohort data
from both studies.
Differences can be observed in the degree of hyperbilirubina-
emia and serum creatinine level between groups. CPS, MELD,
APACHE and SOFA were also more extreme in the tertiary centre
cohort. This could conceivably account for the observedol. 57 j 699–711 707
difference in mortality between the two studies. A categorical Chi
square comparison shows that outcome was signiﬁcantly better
in the non-transplant centre (Hospital mortality 47% vs. 59%,
p = 0.02), which also experienced a higher proportion of alcohol
related liver disease (85/118 (72%) vs. 263/563 (47%), p <0.001).
Regarding the provision of renal replacement therapy, often
regarded as a harbinger of doom in secondary care ICUs, more
patients received this during their transplant centre ICU stay
(50% vs. 31%, p <0.001) but with identical outcomes (81% vs.
81% mortality, NS). Whether the use of this particular organ sup-
port represents the highest observed incidence of renal failure or
a more aggressive standard of care is difﬁcult to say.
The apparent disparity in CPS and SOFA between the studies
could be accounted for by differences in the assessment and cal-
culation of the encephalopathy and GCS score components. Anec-
dotally, this is a difﬁcult area to reliably assess during data
collections such as these, more so when receiving tertiary trans-
fers who have already been intubated.
Overall, the clinical presentation and individual phenotype of
patients with cirrhosis and acute organ dysfunction remains a
highly variable ﬁeld. As more datasets are published, it seems
clear that these patients continue to have very signiﬁcant levels
of mortality but perhaps not as severe as once thought. Care
should be taken when comparing different datasets and consider-
ation should be given to the patient cohort under scrutiny before
necessarily applying the results to individual local practice.
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Table 1. Comparison of cohort data.
Shawcross et al., 2012 Thomson et al., 2010
Survivors Non-survivors Survivors Non-survivors
Age (yr) 49 [16-87] 51 [17-90] 50 [42.5-55] 50 [43-60.5]
Bilirubin (µmol/L) 63 [31-180] 171 [81-354]* 23 [14-54] 64 [26-227]*
INR 1.4 [1.2-1.8] 1.9 [1.5-2.3]* 1.3 [1.1-1.6] 1.9 [1.6-2.2]*
Albumin (g/L) 24 [20-29] 24 [17-28] 23 [18-28] 19 [16-25]
Sodium (mmol/L) 136 [130-140] 133 [127-139] 138 [134-142] 137 [131-142]
Creatinine (µmol/L) 94 [70-165] 170 [115-233]* 64 [52-103] 140 [77-196]*
CPS 11 [10-12] 13 [11-13]* 8 [8-10] 11 [10-12]*
MELD 18 [11-29] 31 [23-37]* 13 [9-18] 23 [18-29]*
APACHE II 19 [15-24] 26 [22-31]* 14 [11-18] 21 [16-23]*
SOFA 9 [7-11] 13 [10-15]* 4 [3-7] 8 [6-11]*
Data is median [IQR].
⁄p<0.001 within each individual study. n.b.: no statistical comparison has been drawn between studies.
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